NX-5948 Clinical Trials

4 actively recruiting trials across 4 locations

▲ +2 trials since August 2026

Also known as: Bexobrutideg, bexobrutideg

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

Nurix Therapeutics, Inc.4

Indications

Cancer4
Small Lymphocytic Lymphoma (SLL)2
Chronic Lymphocytic Leukemia (CLL)2
Small Lymphocytic Lymphoma2
Chronic Lymphocytic Leukemia2

Phoenix, Arizona1 trial

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Banner MD Anderson Cancer Center

Phase 2

Duarte, California1 trial

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope

Phase 1

Aurora, Colorado1 trial

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Rocky Mountain Cancer Centers

Phase 1/2

Macon, Georgia1 trial

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Central Georgia Cancer Care

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.